Literature DB >> 6792279

Immunochemical relations between pneumococcal group 19 and Klebsiella capsular polysaccharides.

C J Lee, K Koizumi.   

Abstract

Pneumococcal type 19F polysaccharide, contained in the current U.S. licensed pneumococcal vaccine, is a poor immunogen in young children. Capsular polysaccharides of Klebsiella, reported to be cross-reactive with the pneumococcal type 19F, were isolated. Immunochemical relations between pneumococcal group 19 and Klebsiella capsular polysaccharides were studied by immunodiffusion with hyperimmune typing antisera, immune passive hemolysis, and plaque-forming cell response in mice following injection of polysaccharides. Klebsiella K2, K9, K32, K47, and K48 polysaccharides were reported to cross-react with horse pneumococcal type 19 antiserum by direct precipitation. However, these Klebsiella polysaccharides did not react in immunodiffusion with horse or with rabbit pneumococcal 19F and 19A typing antisera. Furthermore, pneumococcal type 19F and 19A polysaccharides did not precipitate with rabbit K2, K9, K32, K47, and K49 typing antisera. The cross-reactivity of the Klebsiella and pneumococcal polysaccharides was studied by 2 other methods. Rabbit pneumococcal 19F antiserum induced by low passive hemolysis of sheep erythrocytes coated with Klebsiella polysaccharides. In contrast, Klebsiella typing antisera exhibited higher hemolytic activity with erythrocytes coated with type 19F polysaccharides. The cross-reactivity of K2 and pneumococcal 19F polysaccharides was also exhibited by the direct IgM plaque-forming cell response. The cross-reactivity, determined by precipitin reactions using animal antisera, may not predict the cross-immunogenicity of purified polysaccharides in humans.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6792279

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  9 in total

1.  Purification and immunogenicity of genetically obtained pneumolysin toxoids and their conjugation to Streptococcus pneumoniae type 19F polysaccharide.

Authors:  J C Paton; R A Lock; C J Lee; J P Li; A M Berry; T J Mitchell; P W Andrew; D Hansman; G J Boulnois
Journal:  Infect Immun       Date:  1991-07       Impact factor: 3.441

2.  Purification and immunochemical properties of Escherichia coli B polysaccharide cross-reacting with Salmonella typhi Vi antigen: preliminary evidence for cross-reaction of the polysaccharide with Escherichia coli K1 antigen.

Authors:  B Szewczyk; A Taylor
Journal:  Infect Immun       Date:  1983-07       Impact factor: 3.441

3.  Precipitating cross-reactions among pneumococcal types.

Authors:  M Heidelberger
Journal:  Infect Immun       Date:  1983-09       Impact factor: 3.441

4.  Streptococcus pneumoniae serotype 1 burden in the African meningitis belt: exploration of functionality in specific antibodies.

Authors:  S Blumental; J C Moïsi; L Roalfe; M Zancolli; M Johnson; P Burbidge; R Borrow; S Yaro; J E Mueller; B D Gessner; D Goldblatt
Journal:  Clin Vaccine Immunol       Date:  2015-02-04

5.  Effect of culture conditions on the structure of Streptococcus pneumoniae type 19A(57) capsular polysaccharide.

Authors:  C J Lee; B A Fraser; R A Boykins; J P Li
Journal:  Infect Immun       Date:  1987-08       Impact factor: 3.441

6.  Epitope specificity of rabbit immunoglobulin G (IgG) elicited by pneumococcal type 23F synthetic oligosaccharide- and native polysaccharide-protein conjugate vaccines: comparison with human anti-polysaccharide 23F IgG.

Authors:  E Alonso de Velasco; A F Verheul; A M van Steijn; H A Dekker; R G Feldman; I M Fernández; J P Kamerling; J F Vliegenthart; J Verhoef; H Snippe
Journal:  Infect Immun       Date:  1994-03       Impact factor: 3.441

7.  Immune response of neonates to pneumococcal polysaccharide-protein conjugate.

Authors:  K T Lin; C J Lee
Journal:  Immunology       Date:  1982-06       Impact factor: 7.397

8.  Induction of Susceptibility to Disseminated Infection with IgA1 Protease-Producing Encapsulated Pathogens Streptococcus pneumoniae, Haemophilus influenzae Type b, and Neisseria meningitidis.

Authors:  Mogens Kilian; Steffen Husby; Jesper Andersen; Zina Moldoveanu; Uffe B Skov Sørensen; Jesper Reinholdt; Hervé Tettelin
Journal:  mBio       Date:  2022-04-14       Impact factor: 7.786

9.  Salivary immune responses to the 7-valent pneumococcal conjugate vaccine in the first 2 years of life.

Authors:  Gerwin D Rodenburg; Elisabeth A M Sanders; Elske J M van Gils; Reinier H Veenhoven; Tomasz Zborowski; Germie P J M van den Dobbelsteen; Andries C Bloem; Guy A M Berbers; Debby Bogaert
Journal:  PLoS One       Date:  2012-10-16       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.